

# American Academy of Pediatrics



DEDICATED TO THE HEALTH OF ALL CHILDREN®

## **Disclosure of Commercial Support for AAP CME Activities**

The AAP gratefully acknowledges support for the 2023 National Conference & Exhibition. The full list of supporters can be found here: <https://aapexperience.org/education-supporters/>

## **Disclosure of Financial Relationships and Mitigation of Conflicts of Interest for AAP CME Activities Grid**

The AAP recognizes that there are a variety of financial relationships between individuals and ineligible companies that require review to identify possible conflicts of interest in a CME activity. The "AAP Policy on Disclosure of Financial Relationships and Mitigation of Conflicts of Interest for AAP CME Activities" is designed to ensure quality, objective, balanced, and scientifically rigorous AAP CME activities by identifying and mitigating all potential conflicts of interest prior to the confirmation of service of those in a position to influence and/or control CME content. AAP has taken steps to mitigate any potential conflicts of interest. The purpose of this policy is to ensure all potential conflicts of interest are identified and mechanisms to mitigate them prior to the CME activity are implemented in ways that are consistent with the public good. The AAP is committed to providing learners with commercially unbiased CME activities.

All AAP CME activities will strictly adhere to the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. In accordance with these Standards, the following decisions will be made free of the control of an ineligible company: identification of CME needs, determination of educational objectives, selection and presentation of content, selection of all persons and organizations that will be in a position to control the content, selection of educational methods, and evaluation of the CME activity.

### **DISCLOSURE OF FINANCIAL RELATIONSHIPS**

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

*All other faculty, planners and staff have disclosed no relevant financial relationships with ineligible companies.*

| <b>Name</b>           | <b>Role</b>        | <b>All Financial Relationships</b><br>(Please indicate Yes or No) | <b>Name of Ineligible Company*</b><br><b>Please list name(s) of entity AND Nature of Financial Relationship(s)</b><br>(Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify) |
|-----------------------|--------------------|---|---|
| Back, Susan           | Faculty            | Yes   | Bracco Diagnostics: Research Grant; Philips Healthcare: Independent Contractor; Siemens Healthineers: Independent Contractor  |
| Baldassari, Christina | Teaching Assistant | Yes   | Inspire: Research Grant   |
| Basu, Sonali          | Faculty            | Yes   | GE Healthcare: Consultant   |
| Berlan, Elise         | Faculty            | Yes   | Merck: Research Grant, Honorarium; Organon Inc: Research Grant  |
| Besner, Gail          | Faculty            | Yes   | Scioto Biosciences, Inc.: Stockholder   |
| Bhatia, Rajeev        | Faculty            | Yes   | Merck: Consultant   |
| Brothers, Kyle        | Faculty            | Yes   | Invitae: Research collaboration   |
| Bryant, Kristina      | Faculty            | Yes   | Pfizer: Principal Investigator; Enanta: Principal Investigator; Gilead: Principal Investigator  |
| Camenga, Deepa        | Faculty            | Yes   | Apex Labs: Research Grant   |
| Campbell, James       | Faculty            | Yes   | Merck: Research Grant, Moderna: Research Grant, GSK: Research Grant, Sanofi: Research Grant, Pfizer: Research Grant   |
| Caserta, Mary         | Faculty            | Yes   | Pfizer: Research Grant; Merck: Research Grant; Moderna: Research Grant  |
| Castonguay, Jessica   | Faculty            | Yes   | Organon Inc: Speakers' Bureau   |
| Chaffee, Tonya        | Planning Group     | Yes   | Organon: Honorarium; Hologic: Consultant  |
| Chung, Wendy          | Faculty            | Yes   | Prime Medicine: Board of Directors  |
| Cianferoni, Antonella | Faculty            | Yes   | Regeneron: Consultant   |
| Cisek, Lars           | Faculty            | Yes   | Richard Wolf: Honorarium  |
| Cole, Conrad          | Faculty            | Yes   | Kate Farms: Advisory Board Member   |
| Curfman, Alison       | Faculty            | Yes   | Imagine Pediatrics: Co-founder  |
| Darbari, Anil         | Faculty            | Yes   | Abbott Nutritionals: Honorarium   |
| Darrow, David         | Teaching Assistant | Yes   | Pierre Fabre Dermatologie: Speaker's Bureau   |
| Dave, Sneha           | Faculty            | Yes   | Syneos Health: Advisory Board   |
| Davis, Alexis         | Moderator          | Yes   | Lansing: Advisory Board   |

**DISCLOSURE OF FINANCIAL RELATIONSHIPS**

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

| Name                       | Role                               | All Financial Relationships<br>(Please indicate Yes or No) | Name of Ineligible Company*<br>Please list name(s) of entity AND Nature of Financial Relationship(s)<br>(Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify) |
|----------------------------|------------------------------------|--|---|
| Di Lorenzo, Carlo          | AAP Section/Council Program Chair  | Yes  | NeurAxis: Consultant; Takeda: Consultant; QOL, Inc: Consultant; Mallinckrodt: Consultant; Allergan: Consultant  |
| Diasio, Christoph          | Faculty                            | Yes  | Pfizer: Sub-Principal Investigator  |
| El Feghaly, Rana           | Faculty                            | Yes  | Merck: Research Grant   |
| Farhat, Walid              | Faculty                            | Yes  | Richard Wolf Medical Instruments Corp: Consultant   |
| Fields, Errol              | AAP Section/Council Program Chair  | Yes  | Gilead Sciences: Advisory Board Member; Roche Diagnostics: Advisory Board Member  |
| Foglia, Elizabeth          | Faculty                            | Yes  | Chiesi USA: Research grant, Consultant; Medtronic: Consultant   |
| Fox, Claudia               | Faculty                            | Yes  | Novo Nordisk: Contractor  |
| Fuerch, Janene             | Teaching Assistant                 | Yes  | Laborie: Consultant, Vitara: Consultant, Avanos: Consultant, Novonate: Advisory Board member, EMME: Board of Directors, EmpoHealth: Advisory Board Member, Keriton: Consultant  |
| Gershanik, Esteban         | Faculty                            | Yes  | Change Healthcare: Consultant; Amgen: Stockholder; Eli Lilly and Co: Stockholder; Johnson and Johnson: Stockholder; Pfizer: Stockholder; Uzobi, Inc: Consultant   |
| Gilgoff, Rachel            | Faculty                            | Yes  | Stronger Brains Inc.: Stockholder   |
| Gillispie-Taylor, Miriah   | Faculty                            | Yes  | Pfizer: Research Grant  |
| Cleason, Mary Margaret     | Faculty                            | Yes  | Hampton Roads Biomedical Research Consortium: Research Grant; Little Otter: Consultant; Woebot: Consultant  |
| Good, Misty                | Faculty                            | Yes  | Evive Biotech: Research Grant   |
| Granberg, Candance         | Faculty                            | Yes  | RestoreX: Stockholder   |
| Gross, Robert              | Faculty                            | Yes  | Rebion: Stockholder   |
| Cuglani, Lokesh            | Faculty                            | Yes  | Microbion Biosciences: Consultant   |
| Guilbert, Theresa          | Faculty                            | Yes  | Sanofi: Honorarium; Regeneron: Honorarium and Research Grant; Sanofi/Amgen/Regeneron: Honorarium; AstraZeneca: Compensation and Honorarium; Novartis: Honorarium; Genentech: Advisory Board Member                        |
| Cutierrez, Luz             | Faculty                            | Yes  | Albiero Pharma: Advisory Board Member   |
| Haemer, Matthew            | Faculty                            | Yes  | Rhythm Pharmaceuticals: Independent Contractor  |
| Harpavat, Sanjiv           | Faculty                            | Yes  | Syneos Health: Advisory Board Member  |
| Harris, Christopher        | AAP Section/Council Abstract Chair | Yes  | Enanta Pharmaceuticals: Employee  |
| Healy, C. Mary             | Faculty                            | Yes  | Moderna: Advisory Board Member; Dexcom inc: Stockholder; Quidel Diagnostics: Stockholder; Vapotherm: Stockholder; Intuitive: Stockholder  |
| Heimall, Jennifer          | Faculty                            | Yes  | CSL Behring: Research Grant; Regeneron: Principal Investigator; ADMA: Principal Investigator; Enzyvant: Principal Investigator;   |
| Hernandez-Trujillo, Vivian | AAP Section/Council Program Chair  | Yes  | CSL Behring, Takeda: Speaker; Enzyvant: Consultant; Aimmune: Advisory Board Member; Pharming: Consultant; Regeneron/Sanofi: Advisory Board Member; kaleo: Spokesperson; Amgen: Honorarium                                 |
| Hijazi, Ziyad              | Faculty                            | Yes  | NuMED Inc; Occlutech: Consultant  |
| Hogan, Angela              | Faculty                            | Yes  | GlaxoSmithKline: Speaker Bureau   |
| Hogue, Grant               | Faculty                            | Yes  | Medtronic: Consultant   |
| Hsu, Daphne                | AAP Section/Council Program Chair  | Yes  | Merck: Site Investigator; Xeltis: Advisory Board Member; Rocket Pharmaceuticals: Advisory Board Member; Bayer: Advisory Board Member  |
| Hubbard, Dena              | Faculty                            | Yes  | Abbott Nutrition: Speaker's Bureau  |
| Hudson, Jeff               | AAP Staff                          | Yes  | CVS: Stockholder  |
| Iacobas, Ionela            | Faculty                            | Yes  | Med Learning Group: Speaker; Novartis: Principal Investigator; Merck: Principal Investigator  |

**DISCLOSURE OF FINANCIAL RELATIONSHIPS**

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

| Name              | Role                               | All Financial Relationships<br>(Please indicate Yes or No) | Name of Ineligible Company*<br>Please list name(s) of entity AND Nature of Financial Relationship(s)<br>(Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)  |
|-------------------|------------------------------------|--|--|
| Jastreboff, Ania  | Faculty                            | Yes  | Novo Nordisk: Advisory Board, Research Grant; Eli Lilly: Advisory Board Member, Research Grant; Pfizer: Advisory Board; Boehringer Ingelheim: Advisory Board; Rhythm Pharmaceuticals: Advisory Board, Research Grant; Intellihealth: Advisory Board; WeightWatchers: Advisory Board; Amgen: Advisory Board; Structure Therapeutics: Advisory Board; Biohaven: Advisory Board; Scholar Rock: Advisory Board; AstraZeneca: Advisory Board; Zealand Pharmaceuticals: Advisory Board |
| Jatana, Kris      | Faculty, Teaching Assistant        | Yes  | Marpac: Royalties; Zotarix, LLC: Shareholder; Landsdowne Labs, LLC: Shareholder; Tivic Health Systems: Stockholder   |
| Jenkins, Renee    | Moderator                          | Yes  | Astra Zeneca: Consultant   |
| Kaelber, David    | Faculty                            | Yes  | Becton, Dickinson and Company: Consultant; Dynavax Technologies Corporation: Consultant; Merck Sharp & Dohme Corporation: Consultant   |
| Kalu, Ibukun      | Faculty                            | Yes  | Pfizer: Co-investigator  |
| Kang, Peter       | Faculty                            | Yes  | Sarepta Therapeutics: Advisory Board Member; NS Pharma: Advisory Board Member; Teneofour: Advisory Board Member; Neurogene: Consultant; Novartis: Consultant   |
| Kasten, Steven    | Faculty                            | Yes  | Pfizer, Inc.: Stockholder; Merck & Co., Inc.: Stockholder; Vertex Pharmaceuticals, Inc.: Stockholder; Hologic, Inc.: Stockholder   |
| Kelley, Sarah     | Faculty                            | Yes  | Tarsus Medical: Speaker  |
| Kelly, Aaron      | Faculty/Planning Group             | Yes  | Novo Nordisk: Consultant, Research Grant; Vivus: Consultant, Research Grant; Eli Lilly: Consultant; Boehringer Ingelheim: Consultant   |
| Kim, Jae          | Faculty                            | Yes  | Innara Health: Board of Directors; Ferring Pharmaceutical: Research Grant; Medela: Advisory Board Member; Astarte Medical: Stockholder; Nicolette: Stockholder   |
| Kim, Edwin        | Faculty                            | Yes  | ALK-Abello: Advisory Board Member, Principal Investigator; Ukko Inc: Advisory Board Member; Kenota Health: Advisory Board Member; Allergy Therapeutics Ltd: Review Committee; AllerGenis: Consultant; Belhaven Biopharma: Consultant; Genentech: Consultant; Nutricia: Consultant; Revolo: Consultant; Novartis: Principal Investigator; Genentech: Principal Investigator; DBV Technologies: Principal Investigator; Alladapt: Principal Investigator                           |
| Kirsch, Andrew    | Faculty                            | Yes  | Palette Life Science: Consultant; Intuitive Surgical: Speaker Bureau; Global Continenence Inc: Employee/Owner  |
| Langhan, Melissa  | AAP Section/Council Abstract Chair | Yes  | Takeda pharmaceuticals: Consultant   |
| Lau, May          | Faculty                            | Yes  | Organanon: Honorarium  |
| Marsac, Meghan    | Faculty                            | Yes  | Cellie Coping Company: Employee/Owner  |
| McCrinkle, Brian  | Faculty                            | Yes  | Amryt Pharma: Consultant; Chiesis: Consultant; Esperion: Consultant; Ultragenyx: Consultant  |
| McHenry, Megan    | AAP Section/Council Program Chair  | Yes  | Eli Lilly: Stockholder   |
| Moore, Lindsey    | Faculty                            | Yes  | Aimmune: Speaker Bureau; Kenota Health: Principal Investigator; Evidera: Consultant  |
| Morris, Claudia   | AAP Section/Council Abstract Chair | Yes  | CSL Behring: Consultant; Roche: Consultant   |
| Navsaria, Dipesh  | Faculty, Moderator                 | Yes  | Abbott Labs: Stockholder   |
| Nedved, Amanda    | Moderator                          | Yes  | Pfizer: Principal Investigator; Merck: Principal Investigator  |
| Nicholas, Sarah   | Faculty                            | Yes  | Enzyvant: Advisory Board; Takeda: Honorarium   |
| Nugent, Alan      | Faculty                            | Yes  | PECA, Ltd: Consultant; Edwards: Consultant; Canon: Consultant  |
| Oetgen, Matthew   | Faculty                            | Yes  | Medtronic: Consultant  |
| Orenstein, Walter | Faculty                            | Yes  | Moderna: Advisory Board  |
| Ott, Mary         | Faculty                            | Yes  | Eli Lilly: Stockholder   |
| Parsi, Linda      | Faculty                            | Yes  | Mead Johnson: Speaker Bureau   |

**DISCLOSURE OF FINANCIAL RELATIONSHIPS**

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

| Name                 | Role   | All Financial Relationships<br>(Please indicate Yes or No) | Name of Ineligible Company*<br>Please list name(s) of entity AND Nature of Financial Relationship(s)<br>(Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)  |
|----------------------|--|--|--|
| Patel, Ravi          | AAP Section/Council Program Chair            | Yes  | Infant Bacterial Therapeutics/Premier Research: Data Safety Monitoring Board; Noveome: Advisory Board  |
| Pels, Salley         | Faculty                                      | Yes  | Octopharma: Research Grant; Sobi: Research Grant   |
| Peltier, Christopher | Moderator, AAP Section/Council Program Chair | Yes  | Procter and Gamble: Advisory Board Member; Mead Johnson: Speaker Bureau; By Heart: Speaker Bureau; GSK: Research Grant; Danone Nutrica: Research Grant   |
| Puhl, Rebecca        | Faculty                                      | Yes  | Eli Lilly and Company: Consultant  |
| Raynor, Eileen       | Faculty                                      | Yes  | Inspire Medical: Principal Investigator  |
| Rome, Ellen          | Faculty                                      | Yes  | Organon: Advisory Board Member   |
| Ross, Lainie         | Faculty                                      | Yes  | GE: Stockholder; Bristol-Meyers Squibb: Stockholder; Glaxo: Advisory Board Member; eGenesis: Advisory Board Member   |
| Rossano, Joseph      | Moderator                                    | Yes  | Merck: Consultant; Bayer: Consultant; Bristol Myers Squibb: Consultant   |
| Samuels, Joshua      | Faculty                                      | Yes  | Traverse Pharmaceutical: Research Grant; LAM Pharmaceuticals: Royalties  |
| Santos, Roberto      | Faculty                                      | Yes  | Eli Lilly: Principal Investigator  |
| Sharma, Hemant       | Faculty                                      | Yes  | Aimmune Therapeutics: Research Grant; DBV Technologies: Research Grant   |
| Sicherer, Scott      | Faculty                                      | Yes  | Pfizer: Research Grant   |
| Silverberg, Nanette  | Faculty                                      | Yes  | Regeneron/ Sanofi: Speaker; Verrica: Advisory Board Member; Novan: Advisory Board Member; Incyte: Speaker  |
| Slade, Renee         | Faculty                                      | Yes  | Abbott Laboratories: Stockholder; Alcon, Inc: Stockholder; Costco: Stockholder; Dow, Inc.: Stockholder; General Mills: Stockholder; Honeywell Intl, Inc.: Stockholder; Johnson & Johnson: Stockholder; Novartis: Stockholder; Nvidia Corporation: Stockholder; Proctor & Gamble: Stockholder; UnitedHealth GP, Inc.: Stockholder |
| Smith, Michael       | AAP Section/Council Program Chair            | Yes  | Pfizer: Research Grant   |
| Soghier, Lamia       | Teaching Assistant                           | Yes  | Pyramex: Principal Investigator; Etiometry: Principal Investigator   |
| Sohl, Kristin        | Faculty                                      | Yes  | Cognoa: Research Grant; Quadrant Biosciences: Advisory Board Member  |
| Song, Clara          | Faculty                                      | Yes  | Mead Johnson Nutrition: Speaker Bureau   |
| Strunc, Michael      | Faculty                                      | Yes  | Jazz pharmaceuticals: Speaker Bureau; Takeda Pharmaceuticals: Principal Investigator; Neurelis Pharmaceuticals: Speaker bureau   |
| Stukus, David        | Faculty                                      | Yes  | ARS Pharmaceuticals: Consultant; DBV Technologies: Principal Investigator  |
| Sucato, Daniel       | Faculty                                      | Yes  | Globus Medical: Royalties  |
| Sweeney, Brooke      | Faculty                                      | Yes  | Rhythm: Speaker Bureau, Research Grant; Eli Lilly: Advisory Board Member; Nestle: Advisory Board Member  |
| Urbina, Elaine       | Faculty                                      | Yes  | Astellas Inc.: Advisory Board Member; Targus Medical Inc.: Speaker   |
| Wang, Julie          | Faculty                                      | Yes  | Aimmune Therapeutics: Research Grant; DBV Technologies: Research Grant; Siolta: Research Grant; Regeneron: Research Grant; ALK Abello: DSMB member; Jubilant HollisterStier: Consultant  |
| Weems, Mark          | Faculty                                      | Yes  | Abbott Congenital Heart: Speaker Bureau  |
| White, Patience      | Faculty                                      | Yes  | Pfizer: Stockholder  |
| Yan, Albert          | Faculty                                      | Yes  | Edvyc Health: Employee   |
| Yen, Yi-Meng         | AAP Section/Council Program Chair            | Yes  | Smith-Nephew: Consultant   |
| Yoo, Sylvia          | Faculty                                      | Yes  | Sydnexis: Principal Investigator; Doximity: Stockholder; Horizon Therapeutics: Advisory Board Member   |

**DISCLOSURE OF FINANCIAL RELATIONSHIPS**

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

| Name                | Role                        | All Financial Relationships<br>(Please indicate Yes or No) | Name of Ineligible Company*<br>Please list name(s) of entity AND Nature of Financial Relationship(s)<br>(Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify) |
|---------------------|-----------------------------|--|---|
| Abzug, Joshua       | Presenting Author           | Yes  | Axogen:Consultant; Elsevier:Royalties; Springer:Royalties   |
| Ahmad, Kaashif      | Reviewer                    | Yes  | Aerogen Pharma:Consultant; Aerogen Pharma:Principal Investigator; Sanofi Pasteur:Advisory Board Member  |
| Anderson, John      | Co-Author, Senior Author    | Yes  | Orthopaedics:Research Grant   |
| Andras, Lindsay     | Senior Author, Co-Author    | Yes  | Eli Lilly:Stockholder; Medtronic:Consultant, Speaker Bureau; Nuvasive:Consultant; Nuvasive:Speaker Bureau; Orthobullets:Author; Zimmer Biomet:Consultant; Zimmer Biomet:Speaker Bureau                                    |
| Barry, Jim          | Reviewer                    | Yes  | Aerogen:Research Grant  |
| Bijnens, Bart       | Co-Author                   | Yes  | GE Healthcare:Speaker Bureau  |
| Biniwale, Manoj     | Reviewer                    | Yes  | Airway therapeutics:Research Grant; Chiesi:Research Grant; Infant Bacterial Therapeutics:Research Grant; Medtronic:Research Grant; Roche Diagnostics:Research Grant   |
| Bolton, Michael     | Reviewer                    | Yes  | Moderna:Principal Investigator  |
| Brooks, Alison      | Presenting Author           | Yes  | Derm Tech:Stockholder; Elsevier Publishing Co:Royalties; Exact Sciences:Stockholder   |
| Brousseau, David    | Co-Author                   | Yes  | CSL Behring:Consultant  |
| Chen, Clifford      | Reviewer                    | Yes  | Piecostech:Consultant   |
| Christ, Alexander   | Co-Author                   | Yes  | DJ Orthopaedics:other financial/non-financial interests; Intellijoint Surgical:Consultant; Smith & Nephew:Consultant  |
| Coleman, Nailah     | Reviewer                    | Yes  | GoodSport:Advisory Board  |
| Cook, Jill          | Reviewer                    | Yes  | 23nandMe:Stockholder  |
| D Sponseller, Paul  | Co-Author                   | Yes  | Globus Medical:Consultant; Nuvasive:Consultant  |
| Daphtary, Kshama    | Reviewer                    | Yes  | Roche Holdings:Stockholder; Gilead Sciences:Stockholder; Organon & Co:Stockholder; Merck & Co.:Stockholder; Acceleron Pharma:Stockholder  |
| Davis, Alexis       | Reviewer                    | Yes  | Lansing:Advisory Board Member   |
| Duggan, Christopher | Co-Author                   | Yes  | Takeda:Research Grant; UpToDate:Author  |
| Dunn, James         | Co-Author                   | Yes  | Cepheid, Inc.:Speaker Bureau; Diasorin Molecular, Inc.:Advisory Board Member; Luminex, Inc.:Research Grant; Qiagen, Inc.:Research Grant   |
| Ellis, Henry        | Co-Author                   | Yes  | Athrex:Consultant; Orthopediatric:Honorarium  |
| Fang, Jennifer      | Co-Author                   | Yes  | Teladoc Health:Royalties  |
| Farhat, Walid       | Presenting Author, Reviewer | Yes  | NeoCirc LLC:Leadership Position; Richard Wolf Medical Instrument Corp:Consultant; Xpan Inc:Employee/Owner   |
| Florin, Todd        | Reviewer                    | Yes  | Diasorin:Consultant   |
| Flynn, John         | Co-Author                   | Yes  | Biomet:Consultant   |
| Fornari, Eric       | Co-Author, Senior Author    | Yes  | GE Healthcare:Consultant  |
| Franco, Israel      | Senior Author, Reviewer     | Yes  | Astellas:Consultant; Driqhealth:Advisory Board; Gogoban:Employee/Owner; Gogoban:Research Grant ; Gogoban:Stockholder  |
| George, Alfred      | Senior Author               | Yes  | Neurocrine Biosciences:Research Grant; Praxis Precision Medicines:Consultant, Research Grant; Tevard Biosciences:Advisory Board Member; Tevard Biosciences:Research Grant   |
| Gertz, Shira J.     | Reviewer                    | Yes  | Bristol-Myers Squibb Co:Stockholder; Gilead Sciences Inc:Stockholder; Humana Inc:Stockholder; Merck:Stockholder; Pfizer:Stockholder; Vertex Pharmaceuticals:Stockholder   |
| Goldstein, Rachel   | Co-Author                   | Yes  | Organon:Consultant  |
| Golombek, Sergio    | Reviewer                    | Yes  | Prolacta Biosciences:Speaker Bureau   |

**DISCLOSURE OF FINANCIAL RELATIONSHIPS**

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

| Name              | Role                        | All Financial Relationships<br>(Please indicate Yes or No) | Name of Ineligible Company*<br>Please list name(s) of entity AND Nature of Financial Relationship(s)<br>(Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify) |
|-------------------|-----------------------------|--|---|
| Gomez, Jaime      | Senior Author, Co-Author    | Yes  | Stryker:Consultant; Zimmer Spine:Consultant   |
| Good, Misty       | Reviewer                    | Yes  | Evive Biotech, Inc.:Principal Investigator; Evive Biotech, Inc.:Research Grant  |
| Görges, Matthias  | Co-Author                   | Yes  | Careteam Technologies Inc:Research Grant; Excelar Technologies:Research Grant; Smile CDR Inc:Research Grant; Thrive Health Inc:Research Grant   |
| Greiner, Mary     | Reviewer                    | Yes  | Cordata:Consultant  |
| Grimbly, Chelsey  | Co-Author                   | Yes  | Alexion:Consultant; Ultragenyx:Research Grant   |
| Gupta, Purnendu   | Co-Author                   | Yes  | Depuy Synthes:Speaker Bureau  |
| Gwynn, Lisa       | Presenting Author, Reviewer | Yes  | Merck:Consultant  |
| Hackam, David     | Co-Author                   | Yes  | Abbott Nutrition:Research Grant   |
| Hackell, Jesse    | Reviewer                    | Yes  | ALK Pharmaceuticals:Advisory Board Member   |
| Haddas, Ram       | Co-Author                   | Yes  | Aspen Medical Products:Research Grant; Medtronics:Consultant, Research Grant; SI-Bone:Research Grant  |
| Hageman, Joseph   | Reviewer                    | Yes  | Owlet, Inc.:Advisory Board, Stockholder   |
| Hair, Amy         | Reviewer                    | Yes  | Mead Johnson Nutrition:Research Grant   |
| Hanley, James R.  | Reviewer                    | Yes  | Cardinal Health:Stockholder; Merck Sharpe:Stockholder; Pfizer:Stockholder   |
| Hedequist, Daniel | Co-Author                   | Yes  | Medtronic:Consultant  |
| Hertz, Andrew     | Presenting Author           | Yes  | eSimplify:Consultant; Innovaccer:Consultant; VitalXChange:Consultant; Zest Pediatric Network:Employee/Owner   |
| Hillstrom, Howard | Co-Author                   | Yes  | Biomed Consulting:Board of Directors; Biomed Consulting:Employee/Owner; Biomed Consulting:Principal Investigator; Biomed Consulting:Research Grant  |
| Hinson, Jeremiah  | Co-Author                   | Yes  | Beckman Coulter:Consultant; Beckman Coulter:Research Grant  |
| Hogue, Grant      | Co-Author, Senior Author    | Yes  | Medtronic:Consultant  |
| Hsu, Daphne       | Reviewer                    | Yes  | Bayer Pharma:Advisory Board Member; Rocket Pharmaceutical:Advisory Board Member; Xeltis:Advisory Board Member   |
| Hubbard, Dena     | Reviewer                    | Yes  | Abbott Nutrition:Speaker Bureau   |
| Ignacio, Romeo    | Co-Author                   | Yes  | Abbott Laboratories:Stockholder; AbbVie:Stockholder   |
| Kamidani, Satoshi | Co-Author                   | Yes  | Pfizer:Research Grant   |
| Karpen, Heidi     | Reviewer                    | Yes  | Prolacta Bioscience, Inc:Principal Investigator; Prolacta Bioscience, Inc:Research Grant  |
| Kay, Robert       | Senior Author               | Yes  | Johnson & Johnson:Stockholder; Medtronic:Stockholder; Pfizer:Stockholder; Zimmer Bliomet:Stockholder  |
| Kiapour, Ata      | Senior Author               | Yes  | Miach Orthopedics:Consultant  |
| Kocher, Mininder  | Co-Author                   | Yes  | OrthoPediatrics:Consultant; Ossur:Consultant; Smith and Nephew:Consultant;  |
| Koehler, Ryan     | Co-Author                   | Yes  | Arthrex:Lab participant   |
| Kumar, Parvathi   | Reviewer                    | Yes  | ReAlta Life Sciences:Employee/Owner   |
| Langhan, Melissa  | Reviewer                    | Yes  | Takeda Pharmaceuticals:Consultant   |
| Lau, May          | Reviewer                    | Yes  | Organon: Honorarium   |
| Lawrence, J. Todd | Senior Author, Co-Author    | Yes  | Sawbones/Pacific Research Laboratories:royalties  |
| Levin, Scott      | Co-Author                   | Yes  | Beckman Coulter:Employee/Owner  |
| Li, Ying          | Co-Author                   | Yes  | Medtronic:Advisory Board Member   |
| Lohr, Jami        | Reviewer                    | Yes  | Abbott Laboratories:Consultant  |

**DISCLOSURE OF FINANCIAL RELATIONSHIPS**

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

| Name                     | Role                        | All Financial Relationships<br>(Please indicate Yes or No) | Name of Ineligible Company*<br>Please list name(s) of entity AND Nature of Financial Relationship(s)<br>(Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify) |
|--------------------------|-----------------------------|--|---|
| Louer, Craig             | Senior Author               | Yes  | DePuy Synthes Spine:Consultant; NuVasive:Educational and Financial Support for Research Fellow; POSNA:Research Grant  |
| Mardjetko, Steven        | Reviewer                    | Yes  | Implanet:Consultant; Principal Investigator; Spinecraft:Advisory Board Member, Board of Directors; Spinecraft:Employee/Owner  |
| Markel, Troy             | Senior Author               | Yes  | Noveome Biotherapeutics:Consultant  |
| Markert, James           | Co-Author                   | Yes  | Aettis:Advisory Board Member; Amgen:Stockholder; Treovir:Stockholder  |
| McMahon, Lisa            | Co-Author                   | Yes  | Atricure:Consultant   |
| Meisel, Erin             | Co-Author                   | Yes  | Joint Development LLC:Stockholder; TISSIUM:Consultant   |
| Mendenhall, Shaun        | Co-Author                   | Yes  | Polynovo:Consultant   |
| Mogayzel, Peter          | Co-Author                   | Yes  | 4D Medical:Principal Investigator; Eloxx Pharmaceuticals:Principal Investigator; Vertex Pharmaceuticals:Principal Investigator  |
| Mokshagundam, Deepa      | Reviewer                    | Yes  | CareDx:Advisory Board Member  |
| Morris, Claudia          | Co-Author, Reviewer         | Yes  | CSL Behring:Consultant; Roche:Consultant  |
| Nadler, Evan             | Senior Author               | Yes  | Novo Nordisk:Advisory Board Member; Rhythm Pharmaceuticals:Advisory Board Member  |
| Nedved, Amanda           | Presenting Author, Reviewer | Yes  | Merck:Principal Investigator; Pfizer:Principal Investigator   |
| Newburger, Jane          | Co-Author                   | Yes  | Bristol Myer Squibb: Advisory Board; Pfizer: Advisory Board, Consultant, Research Grant; Daichii Sankyo:Advisory Board; Novartis:Advisory Board   |
| Noonan, Kenneth          | Co-Author                   | Yes  | Medtronic:Consultant  |
| Notrica, David           | Co-Author                   | Yes  | Atricure:Consultant; KLS:Consultant   |
| Pace, J. Lee             | Senior Author               | Yes  | Arthrex, Inc:Consultant, Expert Reviewer; JRF Ortho:Consultant  |
| Pacicca, Donna           | Senior Author, Reviewer     | Yes  | Gilead Sciences:Stockholder; Medtronic:Stockholder; Walgreens Boots:Stockholder; Zimmer Biomet:Stockholder  |
| Padilla, Benjamin        | Co-Author                   | Yes  | Atricure:Consultant   |
| Parton, Lance            | Senior Author               | Yes  | Chiesi Pharmaceuticals, Inc: Speakers Bureau, Consultant; Mallinckrodt Pharmaceuticals: Speakers Bureau, Consultant   |
| Peltier, Chris           | Reviewer                    | Yes  | By Heart:Research Grant; Danone Nutrica:Research Grant; GSK:Research Grant; Mead Johnson:Speaker Bureau; Procter and Gamble:Advisory Board Member   |
| Perks, Patti             | Co-Author                   | Yes  | American Regent, Inc:Advisory Board Member, Consultant; Prolacta Bioscience:Advisory Board Member   |
| Podeszwa, David          | Co-Author                   | Yes  | Orthofix:Consultant   |
| Queen, Katie             | Presenting Author           | Yes  | Limbitx:Consultant; Novo Nordisc:Speaker Bureau; Rhythm Pharmaceuticals:Advisory Board Member, Consultant, Speaker Bureau   |
| Ramsey, Nicole           | Reviewer                    | Yes  | Pfizer:Research Grant   |
| Ravindran, Jayalakshmi   | Reviewer                    | Yes  | Aerogen Pharma Corp.:Principal Investigator   |
| Reed, Jennifer           | Reviewer                    | Yes  | Becton Dickinson:Stockholder; CVS Caremark:Stockholder; Intuitive Surgical:Stockholder; Stryker:Stockholder; Thermo Fischer Scientific:Stockholder; United Health Group:Stockholder                                       |
| Ross, Julie              | Reviewer                    | Yes  | SunTech Medical:Principal Investigator  |
| Rossano, Joseph          | Reviewer                    | Yes  | AskBio:Consultant; Bayer:Consultant; Bristol Myers Squibb:Consultant; Merck:Consultant  |
| Ryabets-Lienhard, Anna   | Senior Author               | Yes  | Amgen:Principal Investigator; Ascendis:Consultant, Principal Investigator; BioMarin:Consultant; BridgeBio:Consultant; Takeda:Principal Investigator; Ultragenyx:Principal Investigator                                    |
| Salas, Ariel             | Reviewer                    | Yes  | Mead Johnson Nutrition:Advisory Board Member, Research Grant; Resbiotic:Consultant  |
| Sanchez-Pinto, L. Nelson | Co-Author                   | Yes  | Allyx, Inc.; Celldom, Inc.; Saccharo, Inc.:Stockholder  |

**DISCLOSURE OF FINANCIAL RELATIONSHIPS**

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

| Name              | Role                               | All Financial Relationships<br>(Please indicate Yes or No) | Name of Ineligible Company*<br>Please list name(s) of entity AND Nature of Financial Relationship(s)<br>(Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)   |
|-------------------|------------------------------------|--|---|
| Sankar, Wudbhav   | Senior Author                      | Yes  | Siemens:Consultant  |
| Santos, Roberto   | Reviewer                           | Yes  | Eli Lilly:Research Grant; Johnson & Johnson:Research Grant; Merck Sharp & Dohme: Research Grant   |
| Sarwahi, Vishal   | Co-Author                          | Yes  | DePuy Synthes:Consultant; Medtronic:Consultant; NuVasive:Consultant; Precision Spine:Consultant, Research Grant   |
| Schlechter, John  | Senior Author, Co-Author           | Yes  | Arthrex Inc:Speaker Bureau  |
| Schulz, Jacob     | Senior Author, Co-Author           | Yes  | OrthoPediatrics:Consultant  |
| Schwend, Richard  | Senior Author, Co-Author, Reviewer | Yes  | OrthoPediatrics:Consultant  |
| Sekhar, Deepa     | Reviewer                           | Yes  | American Kidney Stone Management:Stockholder; United Medical Systems:Equity Interest  |
| Skaggs, David     | Co-Author                          | Yes  | Biomet Spine:Consultant; Green Sun Medical:Stockholder; Ortho Bullets:Advisory Board Member, Consultant, Stockholder; Orthopaedics Today:Board of Directors; Williams & Wilkins:Consultant; Zimmer Biomet:Consultant, Speaker Bureau; Zipline Medical:Stockholder |
| Smith, Aria       | Co-Author                          | Yes  | Beckman Coulter:Employee/Owner  |
| Song, Clara       | Reviewer                           | Yes  | Mead Johnson Nutrition:Speaker Bureau   |
| Sucato, Daniel    | Co-Author                          | Yes  | Globus Medical:Royalties  |
| Swanson, Jonathan | Co-Author                          | Yes  | Aerogen:Research Grant ; Chiesi LLC:Research Grant; Prolacta Bioscience, Inc:Speaker Bureau; Roche:Research Grant; United Therapeutics:Research Grant   |
| Tandon, Animesh   | Reviewer                           | Yes  | Amazon:Stockholder; Medtronic:Advisory Board Member; Medtronic:Consultant; NVIDIA:Stockholder; Realize Medical:Advisory Board Member; Siemens:Consultant; Synergen Health Technologies:Advisory Board Member  |
| Thorne, Julie     | Senior Author                      | Yes  | Bayer Canada:Advisory Board Member; Bayer Canada:Consultant; Organon:Consultant   |
| Torres, Adalberto | Reviewer                           | Yes  | Percussionaire:Speaker Bureau   |
| Travers, Colm     | Reviewer                           | Yes  | Owlet Baby Care Inc.:Research Grant   |
| Tumin, Dmitry     | Senior Author                      | Yes  | Eli Lilly: Research Grant   |
| Vorhies, John     | Co-Author                          | Yes  | Nsite:Advisory Board Member; Nview:Advisory Board Member  |
| Widmann, Roger    | Senior Author                      | Yes  | Medtronic Spine:Consultant; OrthoPediatric Company:Consultant   |
| Yesso, Abigail    | Co-Author                          | Yes  | Magnolia Innovations: Advisory Board; Rocket Pharmaceuticals, Inc.:Advisory Board   |